0001551986-20-000221.txt : 20200708
0001551986-20-000221.hdr.sgml : 20200708
20200708162934
ACCESSION NUMBER: 0001551986-20-000221
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200706
FILED AS OF DATE: 20200708
DATE AS OF CHANGE: 20200708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Darvish Nissim
CENTRAL INDEX KEY: 0001793602
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 201018659
MAIL ADDRESS:
STREET 1: C/O INNOVATE BIOPHARMACEUTICALS, INC.
STREET 2: 8480 HONEYCUTT ROAD, SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273948465
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
4
1
wf-form4_159424015969483.xml
FORM 4
X0306
4
2020-07-06
0
0001551986
9 METERS BIOPHARMA, INC.
NMTR
0001793602
Darvish Nissim
C/O 9 METERS BIOPHARMA, INC.
8480 HONEYCUTT RD, STE 120
RALEIGH
NC
27615
1
0
1
0
Stock Option (Right to Buy)
0.6216
2020-07-06
4
A
0
100000
0
A
2030-07-06
Common stock
100000.0
100000
I
see footnote
The option shall vest in 36 equal monthly installments beginning July 6, 2020.
The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.
/s/ Donald R. Reynolds, as power of attorney
2020-07-08